Taiho Pharma

Executive Summary

Taiho Pharmaceutical, a subsidiary of the Otsuka Group, is a leading Japanese oncology specialist with a strong legacy in oral anticancer agents. Founded in 1963 and headquartered in Tokyo, the company has built a robust pipeline of innovative small molecule drugs targeting oncology, immunology, and urology. With over 1,000 employees and a commercial-stage presence, Taiho maintains significant R&D investment and global commercialization efforts, particularly in Asia and the US. The company's key products include Lonsurf (trifluridine/tipiracil) for colorectal and gastric cancers, and it continues to advance early- and mid-stage candidates in areas like non‑small cell lung cancer (NSCLC), bladder cancer, and immuno‑oncology combinations. Despite being private and lacking a public ticker, Taiho's strategic focus on precision medicine and its integration within the Otsuka group provide financial stability and long-term growth prospects. The company's ability to leverage its expertise in oral chemotherapy and expand into novel mechanisms positions it well in the competitive oncology landscape, though revenue concentration and limited late-stage pipeline diversification remain risks.

Upcoming Catalysts (preview)

• Q2 2026Phase 3 data readout for TAS-114 (a novel antifolate) in NSCLC55% success
• Q4 2026FDA decision on Lonsurf for expanded use in gastric cancer (first-line combination)75% success
• Q1 2027Initial phase 2 results for TAS-119 (an oral PD-1 inhibitor) in solid tumors45% success